**Supplementary Table 2. Univariate and multivariate analyses of PFS**

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| Variables | Univariate analysis | | | | Multivariate analysis | | |
| **β** | **HR (95% CI)** | **P value** | **HR (95% CI)** | | | **P value** | |
| Sex  Female vs male | 0.229 | 1.257 (0.611–2.588) | 0.534 | |  |  | |
| Age, year  >vs ≤54.388 | −0.280 | 0.972 (0.661–1.430) | 0.885 | |  |  | |
| ECOG-PS  0 vs 1 | 0.174 | 1.190 (0.787–1.800) | 0.409 | |  |  | |
| Etiology | −0.024 | 0.976 (0.586–1.625) | 0.925 | |  |  | |
| NLR  ≤ vs >3.125 | 0.069 | 1.839 (1.242–2.723) | 0.002 | | 1.154 (0.755–1.765) | 0.508 | |
| ALBI grade  1 vs 2 | 0.334 | 1.396 (0.946–2.061) | 0.093 | |  |  | |
| Child–Pugh  5 vs 6 and 7 | 0.528 | 1.696 (0.975–2.950) | 0.061 | |  |  | |
| AFP, ng/mL  ≤ vs >400 | 0.596 | 1.815 (1.226–2.687) | 0.003 | | 0.940 (0.593–1.491) | 0.794 | |
| DCP, mAU/mL  ≤ vs >664 | 0.562 | 1.753 (1.160–2.650) | 0.008 | | 1.294 (0.814–2.055) | 0.276 | |
| Target tumor size, cm  ≤ vs >7.5 | −0.156 | 0.856 (0.582–1.258) | 0.429 | |  |  | |
| Target tumor number  1 vs ≥ 1 | 0.095 | 1.100 (0.697–1.737) | 0.682 | |  |  | |
| MVI  absent vs. present | 0.392 | 1.479 (1.002–2.183) | 0.049 | | 0.717 (0.449–1.145) | 0.164 | |
| EHS  Absent vs. present | 0.529 | 1.698 (1.150–2.508) | 0.008 | | 1.700 (1.007–2.869) | 0.047 | |
| BCLC stage  B vs C | 0.552 | 1.738 (1.156–2.611) | 0.008 | | 1.194 (0.655–2.175) | 0.562 | |
| ETS  0: ETS<10%  1: ETS≥10% | 1.542 | 4.672 (2.970–7.349) | ＜0.001 | | 2.577 (1.307–5.083) | 0.006 | |
| DoR  0: DoR<27%  1: DoR≥27% | 1.773 | 5.888 (3.723–9.311) | ＜0.001 | | 3.012 (1.541–5.889) | 0.001 | |

Abbreviations: AFP, alpha-fetoprotein; ALBI, albumin–bilirubin grade; BCLC, Barcelona Clinic Liver Cancer; cm, centimeter; DCP, Des-gamma carboxy prothrombin; DoR, duration of response; EHS, extrahepatic spread; EOCG-PS, Eastern Cooperative Oncology Group Performance Score; ETS, early tumor shrinkage; HR, hazard ratio; mAU, milli-absorbance unit; mL, microliter; MVI, macrovascular invasion; ng, nanogram; NLR, neutrophil-to-lymphocyte ratio; PFS, progression-free survival